Epistra Exhibited at the AMED 'SCARDA Joint Forum 2025'
Epistra, Inc. exhibited at the “SCARDA Joint Forum 2025 — Progress and Outcomes of Infectious Disease Vaccine Research: Toward Deeper Collaboration,” hosted by AMED (Japan Agency for Medical Research and Development) on Wednesday, November 26, 2025.
The forum was organized by AMED’s Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) as a venue for sharing research outcomes and progress on vaccines and novel modalities, with the aim of deepening collaboration among industry, academia, government, and venture capital.
The event brought together numerous researchers and business professionals both on-site and online, with active discussions taking place.
Related Articles
Epistra Contributes Article on "AI-Robot-Driven Drug Development" to Pharmacia, Journal of the Pharmaceutical Society of Japan
Epistra CTO Taku Tsuzuki and CEO Yosuke Ozawa contributed an article on AI-robot-driven drug development to Pharmacia, Vol. 62 No. 7, published by the Pharmaceutical Society of Japan.
Cell Culture Optimization Software 'CellTune Ver.2' Launches Globally
Epistra Inc. announces the global launch of 'CellTune Ver.2,' the updated version of the co-developed cell culture optimization software with Shimadzu Corporation, on June 29, 2026. The new version introduces cloud-based subscription delivery and overseas expansion of custom media manufacturing services.
Speaking Engagement: CEO Yosuke Ozawa Presented at the 10th Shonan iPark Regenerative Medicine Seminar
On June 3, 2026, Epistra Inc. CEO Yosuke Ozawa presented at the 10th Shonan iPark Regenerative Medicine Seminar, sharing implementation case studies and future prospects for AI and mathematical optimization in regenerative medicine process development.